The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors.
P. A. Zucali
No relevant relationships to disclose
M. Simonelli
No relevant relationships to disclose
F. De Vincenzo
No relevant relationships to disclose
E. Lorenzi
No relevant relationships to disclose
L. Rimassa
No relevant relationships to disclose
L. Balzarini
No relevant relationships to disclose
V. Quagliuolo
No relevant relationships to disclose
A. Lambiase
Employment or Leadership Position - MolMed S.p.A.
C. Bordignon
Employment or Leadership Position - MolMed S.p.A.
A. Santoro
No relevant relationships to disclose